Literature DB >> 8813952

Hepatitis virus infection and liver disease in injecting drug users who died suddenly.

E A McCruden1, K J Hillan, I C McKay, M T Cassidy, J C Clark.   

Abstract

AIM: To determine the extent of liver damage resulting from infection with hepatitis B, C and D viruses (HBV, HCV and HDV) in intravenous drug users (IDUs).
METHODS: Liver sections taken at necropsy performed to investigate the cause of sudden death in 48 IDUs were scored for necroinflammatory activity and fibrosis. Evidence of infection was by detection of viral antibodies in serum, hepatitis B surface antigen (HBsAg) and HCV RNA by reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: Evidence of HCV infection was present in 43 (90%) of 48 serum samples. Six (12%) HBsAg positive serum samples had markers indicative of chronic HBsAg carriage, including three with antibody directed against HDV. Evidence of past HBV infection was found in 27 (69%) of 39 HBsAg negative serum samples. HIV was detected in one (2%) of 48 samples. In five (10%) of 48 samples there was no evidence of current or past infection with HCV, HBV or HIV. All 43 liver sections from HCV positive IDUs scored > or = 1 for necroinflammatory activity, whereas three IDUs without HCV scored 0. Scores for stage of fibrosis were > or = 1 in 15 (35%) of 43 and zero of five IDUs, respectively. Fibrosis scores of > or = 3 were seen only in three IDUs positive for HBV, HDV and HCV.
CONCLUSION: Inflammatory activity in the liver is present in a high proportion of IDUs in Glasgow and is strongly associated with HCV infection. Severe chronic liver damage was limited to HBsAg carriers superinfected with HDV and HCV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813952      PMCID: PMC500568          DOI: 10.1136/jcp.49.7.552

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

Review 1.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

Review 2.  Classification of chronic viral hepatitis: a need for reassessment.

Authors:  P J Scheuer
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

3.  Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland.

Authors:  J G Donahue; K E Nelson; A Muñoz; D Vlahov; L L Rennie; E L Taylor; A J Saah; S Cohn; N J Odaka; H Farzadegan
Journal:  Am J Epidemiol       Date:  1991-11-15       Impact factor: 4.897

4.  HIV testing among injecting drug users in Glasgow.

Authors:  R Covell; E Follett; I Coote; M Bloor; A Finlay; M Frischer; D Goldberg; S Green; S Haw; N McKeganey
Journal:  J Infect       Date:  1993-01       Impact factor: 6.072

5.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort).

Authors:  J F Quaranta; S R Delaney; S Alleman; J P Cassuto; P Dellamonica; J P Allain
Journal:  J Med Virol       Date:  1994-01       Impact factor: 2.327

7.  Hepatitis B and hepatitis C in emergency department patients.

Authors:  G D Kelen; G B Green; R H Purcell; D W Chan; B F Qaqish; K T Sivertson; T C Quinn
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

8.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Hepatitis C virus infection detected by antibody tests and the polymerase chain reaction as a cause of liver dysfunction in renal transplant recipients.

Authors:  E A McCruden; S Welch; B Batchelor; M C Allison; B Dow; E A Follett; P R Mills; J D Briggs
Journal:  J Med Virol       Date:  1994-02       Impact factor: 2.327

Review 10.  Natural history of hepatitis C.

Authors:  K Kiyosawa; E Tanaka; T Sodeyama; S Furuta
Journal:  Intervirology       Date:  1994       Impact factor: 1.763

View more
  3 in total

1.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

2.  Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them.

Authors:  K M Roy; S J Hutchinson; S Wadd; A Taylor; S O Cameron; S Burns; P Molyneaux; P G McIntyre; D J Goldberg
Journal:  Epidemiol Infect       Date:  2006-08-08       Impact factor: 2.451

3.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.